Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Immuron enrols first patients into Phase 2 trials for treatment to combat infectious diarrhea
    • News

    Immuron enrols first patients into Phase 2 trials for treatment to combat infectious diarrhea

    Infectious diarrhea could soon be not so infectious with confirmation from biotech company Immuron (ASX: IMC) that the first patients have enrolled for their Phase 2 clinical trial seeking to address issues that arise from unpleasant episodes.  The trial is a response to the persistent challenge of infectious diarrhea among travellers and military personnel deployed

    Read More
    Public
  • Are we in the eye of the inflation storm? | Economic update
    • News

    Are we in the eye of the inflation storm? | Economic update

    During November the market consensus shifted towards the FOMC and ECB remaining on hold throughout 2024. This reflects a forecast that inflation will continue to deflate while unemployment remains low, and the economy keeps growing but at a slow pace. This is the “Goldilocks” scenario. The alternative view is that inflation will begin to rise

    Read More
    Public
  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

    Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments

    Precision microbiome company Microba (ASX: MAP) and the US-based F&B company International Flavors & Fragrances (IFF) have entered the second phase of their joint research initiative, aiming to develop novel microbiome-based treatments for various allergies. The collaboration, a strategic move within the bioscience and health sectors, signals a step forward in addressing the need for

    Read More
    Public
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership
    • News

    RAS Technology dives deeper into European wagering with Playbook Engineering partnership

    Quickly becoming the go-to supplier of critical data within the global wagering industry, RAS Technology (ASX: RTH) has been engaged by Playbook Engineering, a leading UK-based platform provider, for wagering technology, racing data, and editorial content for Playbook’s diverse portfolio of sportsbook brands. The 3-year contract is expected to be valued at $800k per annum

    Read More
    Public
  • BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers
    • News

    BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers

    After becoming a member of the US CLAWS hub in October 2023, semiconductor developer BluGlass (ASX: BLG) has signed its first contract: a $2.6 million (US$1.775m) contract with North Carolina State University (NCSU) to develop lasers in FY24.  As part of its contract for FY24, BluGlass is working on single-frequency DFB (Distributed-feedback) lasers and progressing

    Read More
    Public
  • Markets continue to push higher as Powell signals peak rates
    • Market Update

    Markets continue to push higher as Powell signals peak rates

    The XJO is expected to open higher this morning following a strong night in the U.S on Friday. Their futures have also edged into the green. Over the past few sessions our market has been meekly rising, with Thursday’s strong day breaking the flag pattern (signalled by the break of the short-term descending channel). We

    Read More
    Public
  • «
  • ‹
  • 144
  • 145
  • 146
  • 147
  • 148
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.